Long Wake/Short Sleep Bouts and Hyperactivity with Advanced Age in a Mouse Model of Early Onset Alzheimer’s Disease

This article has 10 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Poor sleep quality and reduced sleep duration are associated with Alzheimer’s disease (AD)-related β-amyloid (Aβ) pathologies. We conducted two studies of sleep/wake, activity and body temperature in App NL-G-F mice, a strain that exhibits three mutations in the human App gene associated with elevated risk for early onset AD. First, App NL-G-F mice were compared to wildtype (WT) littermates at 14-18 and 18-22 months of age and, at both ages, were found to exhibit more Wake and less NREM and REM sleep than WT littermates. This long wake/short sleep phenotype was evident during the dark phase at 14-18 months but occurred in both the light and dark phases at 18-22 months. App NL-G-F mice had fewer short (<60 sec) and more long (>260 sec) Wake bouts and were hyperactive at 18-22 months, which undoubtedly contributed to the increased Wake/reduced sleep. Despite this reduced sleep phenotype, App NL-G-F mice were no sleepier than WT mice and the sleep homeostat was functional in both strains. In the second study, sex differences in these parameters were assessed at 18-24 months. Reduced sleep was evident in both sexes of App NL-G-F mice but was clearly more evident in females. Wake and REM sleep bout durations were longer in both sexes of App NL-G-F mice than in WT littermates. EEG spectral power during NREM sleep was reduced in female App NL-G-F mice between 4.88-10.50 Hz compared to WT mice whereas, during REM sleep, both male and female App NL-G-F mice exhibited reduced spectral power in the theta range. These results suggest that Aβ deposition may impair state transition mechanism(s) in App NL-G-F mice and demonstrate that, as in human AD patients, the long wake/short sleep phenotype was more evident in female App NL-G-F mice, thus supporting the use of this strain as a model to investigate interventions that mitigate AD burden during early disease stages.

Related articles

Related articles are currently not available for this article.